Statin use and mortality of patients with prostate cancer: A meta-analysis

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 1689-1696

  Meng, Yang ^a   Liao, Yan Biao ^a   Xu, Peng ^a   Wei, Wu Ran ^a   Wang, Jia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

All cause mortality; Prostate cancer; Prostate cancer specific mortality; Statins

Indexed keywords

ANDROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CAUSE OF DEATH; DRUG EFFECT; HUMAN; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84961626040     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S97993     Document Type: Article

References (31)

1. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med. 1998;104(2A):2S-5S.
2. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508-519.
3. Dulak J, Jozkowicz A. Antiangiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579-594.
4. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem. 1996;271(29):17453-17462.
5. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7(10):e46691.
6. Katz MS, Carroll PR, Cowan JE, Chan JM, D’Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010;106(5): 627-632.
7. Hamilton R, Vijai J, Gallagher D, et al. Analysis of statin medication, genetic variation and prostate cancer outcomes. J Urol. 2011; (1):e401.
8. Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG. Statin use and fatal prostate cancer: a matched case-control study. Cancer. 2012;118(16):4046-4052.
9. Niraula S, Pond G, de Wit R, Eisenberger M, Tannock IF, Joshua AM. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J. 2013; 7(1-2):E74-E81.
10. Caon J, Paquette M, Hamm J, Pickles T. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy? Prostate Cancer. 2014;2014:184297.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700.
12. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.
13. Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol. 2015;67(6):1122-1133.
14. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013;73(11):1214-1222.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
16. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792-1802.
17. Dehlendorff C, Skriver C, Jespersen CG, et al. Use of statins and prostate cancer mortality. Pharmacoepidemiol Drug Saf. 2014;23:354.
18. Murtola T, Maattanen L, Taari K, Tammela T, Auvinen A. Statin use and survival after prostate cancer diagnosis in the Finnish prostate cancer screening trial. J Urol. 2014; (1):e832.
19. Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32(1):5-11.
20. Calais Da Silva F Jr, Calais Da Silva F Sr, Goncalves F, et al. Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation. Eur Urol Suppl. 2015; 14(2):e563.
21. Chan JM, Kenfield SA, Paciorek A, Platz EA, Giovannucci EL, Stampfer M. Post-diagnostic statin use and the risk of lethal prostate cancer in the health professionals follow-up study. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1638-1640.
22. Hamilton R, Ding K, Crook J, et al. The association between statin use and outcomes in patients initiating androgen deprivation therapy. J Urol. 2015; (1):e930.
23. Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 2003;9(1):10-19.
24. Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16(4):508-519.
25. Cattarino S, Seisen T, Drouin SJ, et al. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. Can J Urol. 2015;22(2):7703-7708.
26. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol. 2005;27(5):1401-1409.
27. Chao C, Jacobsen SJ, Xu L, Wallner LP, Porter KR, Williams SG. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int. 2013;111(6):954-962.
28. Roy M, Kung H-J, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res. 2011;1(4):542-561.
29. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer. 2011; 47(6):819-830.
30. Stelloo S, Nevedomskaya E, van der Poel HG, et al. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 2015; 7(11):1450-1464.
31. Mafuvadze B, Liang Y, Hyder SM. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. Oncol Rep. 2014;32(4):1727-1733.